Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Gut Microbiota As a Target in the Pathogenesis of Metabolic Disorders: A New Approach to Novel Therapeutic Agents Publisher Pubmed



Ejtahed HS1 ; Soroush AR1 ; Angoorani P1 ; Larijani B2 ; Hasaniranjbar S1, 2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Endocrinology and Metabolism Research Institute (EMRI), Shariati Hospital North Kargar Ave, Tehran, 1411413137, Iran

Source: Hormone and Metabolic Research Published:2016


Abstract

As the prevalence of metabolic disorders increases dramatically, the importance of identifying environmental factors affecting metabolism control becomes greater accordingly. Gut microbiota, a complex ecosystem inhabiting the human gastrointestinal tract, is one of these potential factors. Recently, the evidence has shown the associations between alteration in gut microbiota composition and obesity, diabetes, and osteoporosis. However, the causality of gut microbiota on metabolic health has yet to be explored in intervention studies and the underlying mechanisms need to be investigated more in depth. Gut microbiota plays critical roles in the control of immunity, food intake, lipid accumulation, production of short chain fatty acids, insulin signaling, and regulation of bone mass. The gut microbiota represents a novel potential therapeutic strategy for the treatment of metabolic disorders. In this review, we provide insights into the role of the gut microbiota in metabolic disorders and its modulating interventions such as prebiotics, probiotics, and fecal microbiota transplantation. © Georg Thieme Verlag KG Stuttgart, New York.
Other Related Docs
10. Gut Microbiota Composition in Obese and Normal Weight Adults in Iran, Journal of Mazandaran University of Medical Sciences (2021)
12. Gut Microbiota-Derived Metabolites in Obesity: A Systematic Review, Bioscience of Microbiota# Food and Health (2020)
16. Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer, International Archives of Allergy and Immunology (2022)
18. Non-Alcoholic Fatty Liver Diseases: From Role of Gut Microbiota to Microbial-Based Therapies, European Journal of Clinical Microbiology and Infectious Diseases (2020)
21. Gut Microbiota in Nonalcoholic Fatty Liver Diseases With and Without Type-2 Diabetes Mellitus, European Journal of Gastroenterology and Hepatology (2021)
23. Gut Microbiome and Multiple Sclerosis: New Insights and Perspective, International Immunopharmacology (2020)
24. The Landscape of Microbiota Research in Iran; a Bibliometric and Network Analysis, Journal of Diabetes and Metabolic Disorders (2020)
27. Probiotics As a New Regulator for Bone Health: A Systematic Review and Meta-Analysis, Evidence-based Complementary and Alternative Medicine (2021)
29. Inspection of Heritable Gut Microbiota Roles in Obesity, Journal of Biological Regulators and Homeostatic Agents (2023)
34. Spondyloarthropathies and Gut Microbiota, Ankylosing Spondylitis - Axial Spondyloarthritis: Cellular# Molecular and Environmental Factors (2021)
39. A Brief Overview on the Use of Probiotics to Treat Overweight and Obese Patients, Expert Review of Endocrinology and Metabolism (2020)
41. Gut Microbiota and Covid-19: A Systematic Review, Health Science Reports (2023)